Navigation Links
Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
Date:6/4/2009

ABBOTT PARK, Ill., June 4 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and AstraZeneca announced today that they have entered into an agreement for AstraZeneca to co-promote Abbott's TRILIPIX(R) (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote TRILIPIX alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.

"Abbott's portfolio of lipid therapies is designed to help physicians manage a patient's total lipid profile," said Jeffrey Stewart, divisional vice president, Primary Care, Abbott. "With AstraZeneca's established presence in the cardiovascular space, this agreement allows Abbott to expand visibility and education of TRILIPIX among physicians whose patients may benefit from this medication."

"Part of AstraZeneca's corporate strategy is to establish successful external collaborations. AstraZeneca has a long-standing commitment to cardiovascular health and has an established presence in the cholesterol market. This agreement allows us to further strengthen our presence with physicians by including TRILIPIX as an offering to physicians for patients with dyslipidemia," said Jim Helm, vice president, cardiovascular, AstraZeneca US. "With clinical data to support its use in helping certain patients with mixed dyslipidemia to manage all three key lipids, TRILIPIX is another important therapeutic option we can now offer physicians."

TRILIPIX is a prescription medicine that is used along with diet to lower triglycerides and LDL (bad) cholesterol, and increase HDL (good) cholesterol. TRILIPIX is also used along with diet to lower triglycerides and increase HDL cholesterol in people who are at high risk of heart disease and are taking a statin medicine to control their LDL cholesterol. TRILIPIX has not been shown to prevent heart attacks or stroke more than a statin alone.

TRILIPIX should not be taken by people with liver, gallbladder, or severe kidney disease or by nursing mothers. People should tell their healthcare providers about all the medicines they take. Blood tests are needed before and during treatment with TRILIPIX to check for liver problems. A healthcare provider should be contacted if serious side effects such as unexplained muscle pain, tenderness, or weakness develop. The risk of these side effects may be higher when TRILIPIX is used with a statin. Other serious side effects may include abdominal pain, nausea, or vomiting.

About the Agreement

This agreement is the second co-promotion agreement between AstraZeneca and Abbott. In August of 2008, the companies announced a non-exclusive agreement for Abbott to co-promote AstraZeneca's CRESTOR(R) alongside AstraZeneca in the United States.

Important Safety Information About TRILIPIX(R) (fenofibric acid)

TRILIPIX should not be taken by people with liver, gallbladder, or severe kidney disease, nursing mothers, or those allergic to any product ingredient. Unexplained muscle pain, tenderness, or weakness, particularly when occurring with tiredness and fever, may be a sign of a serious side effect and should be reported to a healthcare provider right away. Rarely, muscle-related problems can cause kidney damage and can be fatal. The risk of these side effects may be increased when TRILIPIX is used with a statin. Patients should tell their healthcare provider about all the medicines they take. Blood tests should be performed before and during treatment with TRILIPIX to check for liver or kidney problems. Patients should contact their healthcare provider if they experience abdominal pain, nausea, or vomiting while taking TRILIPIX. These may be signs of inflammation of the gallbladder or pancreas. Women who are pregnant should not take statins and should talk with their healthcare provider about TRILIPIX if they are pregnant or may become pregnant. The most common side effects with TRILIPIX include headache, heartburn, nausea, muscle aches, and increases in muscle or liver enzymes that are measured by blood tests. Full Prescribing Information is available at www.rxabbott.com/pdf/trilipix_pi.pdf. Visit www.trilipix.com or call Abbott Medical Information at 1-800-633-9110 for more information about TRILIPIX.

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.

For more information visit www.astrazeneca.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott; AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... ... Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch of ... headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra FIT ... development, a healthy lifestyle, or mental and physical healing. The week-long wellness program combines ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... to its innovative Unified Instance Manager architecture, meeting the needs of multichannel ... version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides greater ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Medical Center has been recognized for adherence to the highest standards of ... medical accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , ...
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Affordable Care Act. Dr. Botelho advocates for the mass media launching of story ... people ongoing opportunities to share their unfortunate experiences; such a movement can generate ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... LAVAL, Quebec , Dec. 8, 2016 /PRNewswire/ ... and TSX: VRX) ("Valeant") today announced positive ... vehicle-controlled clinical study to assess the safety and ... in the treatment of plaque psoriasis. ... adult subjects with moderate to severe psoriasis, IDP-118 ...
(Date:12/8/2016)... -- Mederi Therapeutics Inc . hat die behördliche Zulassung durch die ... Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the ... at Wuhan Union Hospital ...
(Date:12/8/2016)... , Dec. 8, 2016  Boehringer Ingelheim announced today ... Equality Index (CEI). This is the ninth time that ... designated as a Best Place to Work for LGBT ... CEI is a national benchmarking report on corporate policies ... bisexual and transgender (LGBT) employees. "We ...
Breaking Medicine Technology: